Novo Nordisk has just reported better-than-expected full-year results, with both revenues and profits lifted by 25% thanks to rocketing sales of its semaglutide GLP-1 agonist blockbusters, Ozempic for diabetes and Wegovy for obesity.
Novo Believes ‘Personalized’ Dosing Will Help CagriSema Shine
Investors sold off shares after Novo’s disappointing Cagrisema readout in December, but the company believes more trial results will show it can be the future of obesity treatment.
